Abstract

ObjectivesTo evaluate early effects of tocilizumab (TCZ) on synovitis, bone edema and tenosynovitis by hand MRI in patients with active RA and inadequate response to anti-TNF.MethodsPatients with active RA (DAS28...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis.
Jia Wang ... Sheng-Xiao Zhang
Frontiers in immunology | VOL. 15
Jia Wang, et. al.Jia Wang ... Sheng-Xiao Zhang
22 Apr 2024
FRI0225 Short Course of Tocilizumab Increases Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Rheumatoid Arthritis: A Real-World, Prospective Cohort Study
J Jing ... D.-H Zheng
Annals of the Rheumatic Diseases | VOL. 75
J Jing, et. al.J Jing ... D.-H Zheng
01 Jun 2016
AB0570 Response of active rheumatoid arthritis to the anti-interleukin 6 (anti-IL 6) receptor antibody tocilizumab: Evaluation by magnetic resonance imaging
R Samira ... H.-H Najia
Annals of the Rheumatic Diseases | VOL. 71
R Samira, et. al.R Samira ... H.-H Najia
01 Jun 2013
SAT0183 Patient Reported Outcomes (PRO) of the Mirai: Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed by Rituximab in DMARD-IR Patients with Rheumatoid Arthritis (MIRAI)
R Schwenke ... G.-R Burmester
Annals of the Rheumatic Diseases | VOL. 74
R Schwenke, et. al.R Schwenke ... G.-R Burmester
01 Jun 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers